Xiaopeng Peng

1.1k total citations · 1 hit paper
55 papers, 750 citations indexed

About

Xiaopeng Peng is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Xiaopeng Peng has authored 55 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Organic Chemistry and 10 papers in Oncology. Recurrent topics in Xiaopeng Peng's work include Protein Degradation and Inhibitors (17 papers), Histone Deacetylase Inhibitors Research (15 papers) and Catalytic C–H Functionalization Methods (8 papers). Xiaopeng Peng is often cited by papers focused on Protein Degradation and Inhibitors (17 papers), Histone Deacetylase Inhibitors Research (15 papers) and Catalytic C–H Functionalization Methods (8 papers). Xiaopeng Peng collaborates with scholars based in China, United States and Thailand. Xiaopeng Peng's co-authors include Jianjun Chen, Shijun Wen, Zhiqiang Sun, Weijie Peng, Yichang Ren, Peng Huang, Jingxuan Chen, Zhenhua Gu, Feng Jiang and Fuhai Wu and has published in prestigious journals such as Chemical Reviews, Angewandte Chemie International Edition and Journal of Medicinal Chemistry.

In The Last Decade

Xiaopeng Peng

50 papers receiving 742 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HDAC-targeting epigenetic modulators for cancer immunotherapy

2024 58 citations Binbin Cheng, Yao Xiao et al. European Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaopeng Peng China	16	421	322	173	36	36	55	750
Ferdinando Maria Milazzo Italy	15	448 1.1×	218 0.7×	163 0.9×	22 0.6×	41 1.1×	30	692
Qinsheng Sun China	18	576 1.4×	293 0.9×	176 1.0×	45 1.3×	31 0.9×	35	807
Seojeong Park South Korea	14	318 0.8×	178 0.6×	165 1.0×	59 1.6×	32 0.9×	33	578
Cunlong Zhang China	17	379 0.9×	266 0.8×	132 0.8×	44 1.2×	29 0.8×	32	641
So Ha Lee South Korea	16	323 0.8×	437 1.4×	118 0.7×	71 2.0×	19 0.5×	49	690
Ying‐Chao Duan China	13	659 1.6×	479 1.5×	108 0.6×	20 0.6×	30 0.8×	27	1.1k
Sarbjit Singh United States	14	161 0.4×	369 1.1×	98 0.6×	31 0.9×	53 1.5×	38	608
Julienne K. Muenzner Germany	16	245 0.6×	357 1.1×	295 1.7×	35 1.0×	28 0.8×	19	745
Sung Yun Cho South Korea	15	356 0.8×	277 0.9×	115 0.7×	66 1.8×	81 2.3×	43	673
Homayon J. Arabshahi New Zealand	11	221 0.5×	254 0.8×	155 0.9×	18 0.5×	17 0.5×	17	499

Countries citing papers authored by Xiaopeng Peng

Since Specialization

Citations

This map shows the geographic impact of Xiaopeng Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaopeng Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaopeng Peng more than expected).

Fields of papers citing papers by Xiaopeng Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaopeng Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaopeng Peng. The network helps show where Xiaopeng Peng may publish in the future.

Co-authorship network of co-authors of Xiaopeng Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaopeng Peng. A scholar is included among the top collaborators of Xiaopeng Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaopeng Peng. Xiaopeng Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Binbin, et al.. (2025). Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates. European Journal of Medicinal Chemistry. 287. 117347–117347. 1 indexed citations

Peng, Xiaopeng, et al.. (2025). RF-Sauron: Enabling Contact-Free Interaction on Eyeglass Using Conformal RFID Tag. IEEE Internet of Things Journal. 12(10). 14320–14332.

Hu, Zhihao, Shuqing Li, Haiqi He, et al.. (2025). Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. Journal of Medicinal Chemistry. 68(5). 5426–5454. 3 indexed citations

Xie, Ting, et al.. (2025). Kaempferol protects against high-salt-induced hypertension and vascular endothelial injury by inhibiting ferroptosis through the ATF4/ACSL4 pathway. Journal of Functional Foods. 125. 106684–106684. 1 indexed citations

Li, Shuqing, et al.. (2025). Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy. European Journal of Medicinal Chemistry. 285. 117235–117235. 2 indexed citations

Hu, Zhihao, et al.. (2025). Design, synthesis and bioevaluation of novel hydrazide derivatives as enhancers of immunotherapy and DNA-damage response in antitumor therapy. European Journal of Medicinal Chemistry. 291. 117601–117601. 1 indexed citations

Wu, Chengyong, Ling Li, Jin Liu, et al.. (2024). Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma. European Journal of Medicinal Chemistry. 277. 116791–116791. 6 indexed citations

Chen, Weiming, et al.. (2024). HFIP promoted cyclization of o-hydroxyaryl enaminones with chlorohydrocarbon for synthesis of chromone-containing triarylmethanes. Tetrahedron. 156. 133948–133948. 2 indexed citations

Cheng, Jinmei, Zichao Yang, Ting Liu, et al.. (2024). Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects. Journal of Medicinal Chemistry. 67(15). 13067–13088. 9 indexed citations

10.

Cheng, Binbin, et al.. (2024). HDAC-targeting epigenetic modulators for cancer immunotherapy. European Journal of Medicinal Chemistry. 265. 116129–116129. 58 indexed citations breakdown →

11.

Cheng, Binbin, et al.. (2024). Recent advances in developing targeted protein degraders. European Journal of Medicinal Chemistry. 284. 117212–117212. 8 indexed citations

12.

Cheng, Binbin, et al.. (2024). Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024). European Journal of Medicinal Chemistry. 275. 116645–116645. 2 indexed citations

13.

Zhang, Tingyan, Jiuzhong Huang, Xiaopeng Peng, et al.. (2024). Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp. Biomedicine & Pharmacotherapy. 171. 116180–116180. 4 indexed citations

14.

Peng, Xiaopeng, et al.. (2024). P‐48: Evaluation of Field of View in Optical See‐through Near Eye Displays. SID Symposium Digest of Technical Papers. 55(1). 1548–1550. 1 indexed citations

15.

Huang, Jiuzhong, Yi Wu, Zhihao Hu, et al.. (2023). Mn(OAc)2-promoted [3+2] cyclization of enaminone with isocyanoacetate: Rapid access to pyrrole-2-carboxylic ester derivatives with potent anticancer activity. Bioorganic Chemistry. 140. 106748–106748. 4 indexed citations

16.

Xiao, Hao, et al.. (2023). Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment. European Journal of Medicinal Chemistry. 264. 115999–115999. 7 indexed citations

17.

Yang, Zichao, Xiaopeng Peng, Yao Liu, et al.. (2023). Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation. European Journal of Medicinal Chemistry. 259. 115664–115664. 15 indexed citations

18.

Peng, Xiaopeng, Zhihao Hu, Congcong Xu, et al.. (2023). Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies. Acta Pharmaceutica Sinica B. 14(2). 533–578. 39 indexed citations

19.

Peng, Xiaopeng, et al.. (2023). Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies. European Journal of Medicinal Chemistry. 264. 115982–115982. 22 indexed citations

20.

Peng, Xiaopeng, et al.. (2020). Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry. 208. 112831–112831. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact